Novartis Licenses Stem-Cell Platform for Cell Therapy Portfolio

Related tags Cell therapy Stem cell

Novartis Licenses Stem-Cell Platform for Cell Therapy Portfolio
Novartis has entered a research collaboration with Regenerex in order to enlarge the scope of its novel cell therapy portfolio.

The company will license Regenerex’ hematopoietic stem cell-based Facilitating Cell Therapy (FCRx) platform which, on top of being used in the transplant field, will be used to investigate a number of genetic deficiencies.

“As the field of biomedicine sits on the cusp of a new transformation, we are excited to announce this agreement which supports the Novartis leadership position in cell therapy,”​ said Novartis’ Global Head of Development, Dr. Timothy Wright.

“Thirty years ago, Novartis developed ciclosporin, which changed transplantation treatment paradigms and enabled countless lives to be saved. Now, this collaboration, along with our internal cell therapy assets, has the potential to transform medicine once again through innovation.”

The platform is set to broaden Novartis’ cell therapy portfolio, which includes CTL019, a chimeric antigen receptor T cell therapy currently in Phase II development for leukemia.

Related topics Bio Developments Bio-Outsourcing

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars